Published January 1, 2020 | Version v1
Journal article Open

The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of Tc-99m Labeled Paclitaxel: In Vitro Monitoring in Breast Cancer Cells

  • 1. Ege Univ, Inst Nucl Sci, Dept Nucl Applicat, POB 35100, Izmir, Turkey
  • 2. Ege Univ, Sci Fac, Chem Dept, Izmir, Turkey

Description

Background: Bitter Melon Extract (BME) is widely used for the treatment of various diseases worldwide due to its rich phytochemical and antioxidant content. The well-known anti-cancer drug Paclitaxel (PAC) plays a major role in the treatment of various cancer types such as ovarian, breast, and lung cancer. Technetium-99m ((99)mTc) radiolabeled paclitaxel is emerging as an imaging probe for breast cancer in vivo. (99)mTc labeled compounds have been attracting more scientific attention since the achievement of earlier researches in Nuclear Medicine. People consume several types of diets of plant origin without knowing the interaction with radiolabeled compounds or radiopharmaceuticals.

Files

bib-afc8dfc2-1285-4d89-abc2-87b2d0111d96.txt

Files (284 Bytes)

Name Size Download all
md5:775bf4f678ead56b72e4a6b0055a4fe0
284 Bytes Preview Download